trending Market Intelligence /marketintelligence/en/news-insights/trending/7ktSoCNjqACKerQyCYiweg2 content esgSubNav
In This List

Cancer Genetics closes common stock offering

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Cancer Genetics closes common stock offering

Cancer Genetics Inc. closed an underwritten public offering of 13,333,334 common shares at 22.5 cents each.

The company raised gross proceeds of $3 million.

Net proceeds will be used to pay costs related to potential forbearance agreements Cancer Genetics is negotiating with its banks, as well as costs related to on-going strategic initiatives. Remaining funds, if any, will go toward working capital and other general corporate purposes.

Underwriters were granted a 45-day option to buy 2 million additional shares, also at 22.5 cents each.

H.C. Wainwright & Co. acted as the sole book-running manager for the offering.

Rutherford, N.J.-based Cancer Genetics develops, commercializes and provides molecular and biomarker-based tests and services.